Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL L LONG

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1033523329
CMS profile
620487
Location
NEENAH, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$283,307.74

262 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL L LONG

NPI 1033523329 · CMS profile ID 620487

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

NEENAH, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033523329?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL L LONG, NPI 1033523329, CMS profile ID 620487. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033523329?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DANIEL L LONG, NPI 1033523329, CMS profile ID 620487. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033523329?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DANIEL L LONG, NPI 1033523329, CMS profile ID 620487, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1033523329?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

262 matching records · $283,307.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 262 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 262.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $3,766.0008/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1208483822 CMS
EMD Serono, Inc. $477.2608/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236886718 CMS
EMD Serono, Inc. $121.8308/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236883225 CMS
EMD Serono, Inc. $1,419.2008/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236886830 CMS
EMD Serono, Inc. $258.7708/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236887264 CMS
EMD Serono, Inc. $639.3408/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236887494 CMS
Janssen Biotech, Inc. $18.2408/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175361347 CMS
GENZYME CORPORATION $18.4808/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233553515 CMS
Alexion Pharmaceuticals, Inc. $121.1308/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202928884 CMS
Alexion Pharmaceuticals, Inc. $1,000.0008/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202928970 CMS
TG Therapeutics, Inc. $930.0008/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226249914 CMS
Biogen, Inc. $269.0008/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208429744 CMS
Alexion Pharmaceuticals, Inc. $1,862.5008/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202953880 CMS
Alexion Pharmaceuticals, Inc. $102.4508/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202958962 CMS
Biogen, Inc. $538.0008/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208446410 CMS
EMD Serono, Inc. $18.3707/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236907829 CMS
EMD Serono, Inc. $4,463.0007/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236874110 CMS
TG Therapeutics, Inc. $930.0007/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226249910 CMS
GENZYME CORPORATION $22.7507/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233553478 CMS
EMD Serono, Inc. $42.0107/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236908837 CMS
EMD Serono, Inc. $81.9007/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236873966 CMS
EMD Serono, Inc. $1,548.8407/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236888942 CMS
EMD Serono, Inc. $65.0007/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236889202 CMS
GENZYME CORPORATION $23.8607/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233553503 CMS
Biogen, Inc. $23.0307/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208490702 CMS
EMD Serono, Inc. $3,273.0006/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236882581 CMS
Alexion Pharmaceuticals, Inc. $2,580.0006/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202950398 CMS
Alexion Pharmaceuticals, Inc. $2,150.0006/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202959516 CMS
EMD Serono, Inc. $37.8806/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236910241 CMS
Alexion Pharmaceuticals, Inc. $125.0006/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202919744 CMS
Alexion Pharmaceuticals, Inc. $954.0006/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202945868 CMS
ABBVIE INC. $8.4606/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202320720 CMS
Alexion Pharmaceuticals, Inc. $2,580.0006/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202971168 CMS
Tanabe Pharma America, Inc. $19.9406/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243917554 CMS
Alexion Pharmaceuticals, Inc. $104.3706/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202932604 CMS
EMD Serono, Inc. $4,463.0006/06/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236923404 CMS
GENZYME CORPORATION $15.3306/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233553446 CMS
Vanda Pharmaceuticals Inc. $22.5406/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232981778 CMS
ARGENX US, INC. $17.2606/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240427654 CMS
Biogen, Inc. $17.7706/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208364545 CMS
EMD Serono, Inc. $80.0006/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236912461 CMS
Alexion Pharmaceuticals, Inc. $954.0006/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202945260 CMS
Alexion Pharmaceuticals, Inc. $124.9906/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202946776 CMS
TG Therapeutics, Inc. $16.4805/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226249806 CMS
Alexion Pharmaceuticals, Inc. $3,440.0005/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202932124 CMS
Alexion Pharmaceuticals, Inc. $3,440.0005/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202941972 CMS
TG Therapeutics, Inc. $2,557.5005/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226249847 CMS
TG Therapeutics, Inc. $747.2505/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226249860 CMS
TG Therapeutics, Inc. $1,105.8805/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226249824 CMS
TG Therapeutics, Inc. $2,557.5005/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226249856 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,845.46 75
PY2020 $36,035.45 54
PY2021 $74,609.56 106
PY2022 $132,894.95 175
PY2023 $175,049.11 194
PY2024 $189,699.05 203
PY2025 $283,307.74 262

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $72,266.12 110
PY2024 Principal investigator $76,382.55 114
PY2023 Principal investigator $43,855.96 79
PY2022 Principal investigator $40,907.28 9
PY2021 Principal investigator $44,968.40 7
PY2020 Principal investigator $19,521.60 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

110 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628472
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628477
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628482
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628486
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628489
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628493
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628497
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628502
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628506
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628511
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628515
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628520
Principal investigator 1 Roche Products Limited $23.50 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628525
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628529
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628532
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628536
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628542
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628546
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,226.81 08/19/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190302259
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628202
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628205
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628208
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628211
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628215
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628222
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628226
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628230
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628234
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628239
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628244
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628248
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628251
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628255
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628262
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628267
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628270
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628283
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628287
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628292
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628296
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628304
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628313
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628316
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628320
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628323
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628328
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628331
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628336
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628345
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628347
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628351
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628361
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628366
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628371
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628375
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628379
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628386
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628392
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628404
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628409
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628417
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628421
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628424
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628428
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628437
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628440
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628444
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628449
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628453
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628459
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628218
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628275
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628300
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628309
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628341
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628356
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628381
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628389
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628397
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628400
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628413
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628433
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628456
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628463
Principal investigator 1 Roche Products Limited $235.00 04/01/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628467
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,870.81 01/30/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307369
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628096
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628100
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628106
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628112
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628116
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628120
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628124
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628129
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628133
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628137
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628141
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628144
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628149
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628153
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628155
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628160
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628165
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628170
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628177
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628182
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628186
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628190
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628194
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
NEUROSCIENCE GROUP
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628198